Petros Grivas: Genomic biomarkers and response/survival with anti-PD1/L1 in advanced Urothelial Carcinoma
Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, shared a recent article by him and colleagues on X:
“Excited for one more paper from our multi-center database on genomic biomarkers and response/survival with anti-PD1/L1 in patients with advanced urothelial carcinoma.
Kudos to super mentees Rafee Talukder.”
Authors: Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, Leonidas N. Diamantopoulos, Thomas Enright, Jacob B. Leary, Ruben Raychaudhuri, Nishita Tripathi, Neeraj Agarwal, Tanya Jindal, Jason R. Brown, Yousef Zakharia, Macarena Rey-Cárdenas, Daniel Castellano, Charles B. Nguyen, Ajjai Alva, Roubini Zakopoulou, Aristotelis Bamias, Rafael Morales Barrera, David Marmolejo, Alexandra Drakaki, David J. Pinato, James Korolewicz, Lucia Alonso Buznego, Ignacio Duran, Clara Castro Carballeira, Rana R. McKay, Tyler F. Stewart, Shilpa Gupta, Pedro Barata, Evan Y. Yu, Vadim S. Koshkin, Ali Raza Khaki and Petros Grivas
Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance.
He’s an Associate Professor at the Dept. of Medicine and an Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.
More posts featuring Petros Grivas.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023